The role of FDG PET assessment in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 inhibitors in the second-line setting

The role of FDG PET assessment in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 inhibitors in the second-line setting

BackgroundCyclin-dependent kinase 4/6 (CDK4/6) inhibitors have demonstrated a survival benefit in the second-line treatment of patients with hormone receptor-positive human epidermal growth factor receptor 2-negative advanced breast cancer. However, identifying prognostic biomarkers remains a challe...

Full description

Saved in:
Bibliographic Details
Main Authors: Marcin Kubeczko, Anna Polakiewicz-Gilowska, Andrea D’Amico, Olgierd Chrabański, Katarzyna Świderska, Ewa Chmielik, Sławomir Blamek, Daria Handkiewicz-Junak, Michał Jarząb
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-12-01
Series:Frontiers in Oncology
Subjects:
advanced breast cancer
18Ffluorodeoxyglucose positron emission tomography
palbociclib
ribociclib
abemaciclib
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1454844/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1454844/full

Similar Items